The Cohen Laboratory has multiple clinical and basic science research protocols to support the research aims of the laboratory.

Autologous stem cell transplantation for severe refractory Crohn’s disease
– This clinical trial enrolls patients with severe medically refractory Crohn’s disease in a trial of autologous stem cell transplantation. This trial is open to enrollment. Samples are taken during the study for translational analyses including hematopoietic stem cells.

Moving beyond inflammation as a therapeutic target for Crohn’s disease
– This clinical trial enrolls patients with medically refractory Crohn’s disease in a trial of tirzepatide (a GLP1 receptor agonist). The trial aims to be enrolling patients by summer 2025. Samples will be taken for translational studies including epithelial organoids, mesenchymal cells and circulating immune cells.

IBD Natural History
– This is a natural history study of patients with inflammatory bowel disease. It allows for prospective sample collection from patients with IBD and healthy controls. It also aims to integrate structured and unstructured patient datasets leveraging large language models to generate meaningful datasets to query real world patient outcomes.

Bone marrow niche in IBD
– This is a translational study that allows for the sampling of patients with IBD and healthy controls including bone marrow samples.

Stem cell transplantation consortium
– This is an observational international study to understand the long-term outcomes of patients with Crohn’s disease that undergo a stem cell transplantation. The goal of this consortium study is to move stem cell transplant towards a standardized therapy for patients with Crohn’s disease.